Version May 2024
Diagnostic imaging: Adults: IV (based on 70 kg patient): 200 to 500 microCi (7.4 to 18.5 MBq)
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing; start at the lower end of the dosing range.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.
Dermatologic: Urticaria
Hypersensitivity: Hypersensitivity reactions
Miscellaneous: Fever
There are no contraindications listed within the manufacturer’s labeling.
Disease-related concerns:
• Leukopenia: Autologous leukocyte labeling is not recommended in leukopenic patients due to the small number of available leukocytes in this patient population.
Special populations:
• Pediatric: Due to high radiation burden and potential for long-term adverse effects, children <18 years should only be administered indium In-111 oxyquinoline labeled autologous leukocytes when the benefits outweigh the risks.
Special handling:
• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.
Other warnings/precautions:
• Accumulation: Cell clumping can cause accumulation of and prolonged radioactivity in the lungs, thereby leading to false positive results; accumulation can be detected by imaging the chest immediately after injection. Accumulation of labeled leukocytes may also occur in the colon, liver, and accessory spleens and thereby mask inflammatory lesions in these organs. Heart pool activity may occur when labeled leukocytes are contaminated with hemolyzed blood.
• Blood-borne pathogens: Use standard precautions during labeling procedure and administration of labeled autologous leukocytes to prevent blood-borne pathogen transmission.
• Deterioration of chemotaxis: Loss of granulocyte chemotaxis during storage may produce false negative results; injection of labeled autologous leukocytes should occur within 3 hours (preferably within 1 hour) following completion of the cell labeling procedure and ≤5 hours after the initial blood draw.
• Impaired labeling efficiency: Plasma and red cell contamination impairs labeling efficiency of leukocytes.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous:
Generic: 1 mCi/mL (1 ea)
Yes
Solution (Indium In 111 Oxyquinoline Intravenous)
1 mci/mL (per each): $4,634.82
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous:
Generic: 1 mCi/mL (1 mL)
IV: Not for direct IV injection; only indium In-111 oxyquinoline labeled autologous leukocytes may be administered IV. See manufacturer’s labeling for complete administration procedure. Imaging is recommended ~24 hours after administration.
Radiopharmaceutical; use appropriate precautions for handling and disposal. Waterproof gloves should be worn during handling and administration.
Diagnostic imaging: Agent used in radiolabeling autologous leukocytes as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection when localization or diagnosis by other methods (eg, ultrasound or computed tomography) fails or is ambiguous
Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.
None known.
There are no known significant interactions.
Elective examinations in women of reproductive potential should be conducted within 10 days of the onset of menses.
Animal reproductive studies have not been conducted. In a related compound, indium nitrate adverse events were observed in animal reproductive studies.
Indium 111 is excreted in the breast milk. The manufacturer recommends that formula feedings be substituted until radioactivity has cleared.
Creates radiolabeled autologous leukocytes to allow for detection of inflammatory processes such as abscesses or other infections.
Distribution: 30% spleen; 30% liver; 4% to 7.5% pulmonary (radioactivity usually visible only up to ~4 hours after injection); remainder distributed throughout body and red marrow
Half-life elimination: Indium In-111: Physical half-life: 67.2 hours
Excretion: Urine and feces (<1%), mainly through decay to stable cadmium
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
